Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans. — From Psychiatric Times articles Read More
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT